Kornimate/medical-research-clean huggingface dataset:
reduction of post-operative urinary retention with tamsulosin versus placebo (repourt- p) trial

Conditions: Urinary Catheterization; Thoracic Surgery; Thoracic Epidural Analgesia

Summary: the purpose of this study are to determine the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention and improving other clinical outcomes in people undergoing thoracic surgery.

post-operative urinary retention (pour) is not an uncommon complication following thoracic surgery. it has been reported to occur in up to 12-67% of patients with the use of thoracic epidural analgesia1. risk factors associated with urinary retention in thoracic patients include male, age over 40 years, type 2 diabetes, undergoing lung resection and the use of thoracic epidural analgesia2. patients who experience urinary retention are treated with a straight catheter and may subsequently require the placement of an indwelling catheter. the use of these catheters is associated with numerous complications. the best studied complications are infectious and include catheter associated urinary tract infections (cautis). however, many patients continue to experience symptoms well after their catheters have been removed. tamsulosin is an alpha one adrenergic receptor blocked that is indicated for the treatment of lower urinary tract symptoms in the context of benign prostatic hyperplasia. however, it is often used in clinical practice to treat other pathologies such as acute urinary retention and nephrolithiasis. the objectives of this study are to determine the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention and catheter related complications in people undergoing thoracic surgery.

Eligibility criteria:
inclusion criteria: 1. male patients greater than the age of 40 and/or with type 2 diabetes undergoing pulmonary surgery who did not undergo straight or indwelling urinary catheterization intraoperatively. or 2. male patients receiving a thoracic epidural analgesia undergoing pulmonary surgery who did not undergo straight or indwelling urinary catheterization intraoperatively exclusion criteria: 1. active treatment of benign prostatic hyperplasia (bph) 2. hypersensitivity or allergy to tamsulosin hcl 3. active treatment with tamsulosin or other alpha-blocker or uses of tamsulosin/ other alpha-blocker within 3 weeks of enrollment date 4. active urinary tract infection 5. history of urological disorder specified as urethral stricture, bph, bladder or prostate malignancy 6. history of urological surgery (transurethral resection of the prostate, transurethral resection of the bladder, bladder suspension, prostatectomy) 7. underlying neurological disorders resulting in impaired bladder function 8. any known contraindication to the use of tamsulosin hcl

Keywords: post-operative urinary retention tamsulosin urinary tract infections catheter
evaluation of salivary elisa for hormone monitoring in ivf patients

Conditions: Infertility, Female; Reproductive Sterility

Summary: in assisted reproductive treatment (art), it is necessary to follow closely the stimulation cycles of patients undergoing these treatments in order to monitor the number and size of developing follicles. oestradiol (e2) and progesterone (p) are products of steroidogenesis and the concentrations of both hormones increase with the diameter of the growing follicle and accurate and reliable methods to measure e2 and p are essential to assess treatment response and support clinical decision. measurement of both hormones, as well as monitoring of follicle growth through ultrasound measurements, is an important part of ovarian stimulation, requiring patients to undergo multiple blood draws. it is often a physically and emotionally painful process and the most convenient solution to this problem is the measurement of hormone concentration in other biological fluids. salivary diagnostic tests are a less invasive, inexpensive and stress-free alternative to measurements of hormone concentration in other biological fluids. the current study pretends to evaluate the correlation between salivary elisa assays and serum determination of progesterone and oestradiol concentrations ivf patients. in addition, secondary objectives include the measurement of diurnal variability of salivary hormone levels and patient experience with saliva collection as users.


Eligibility criteria:
inclusion criteria: * patients undergoing ivf/icsi treatment * patients planned to embryo transfer (et) undergoing hormonal replacement therapy * aged from18-45 years old. * bmi 19-30 kg/m2 * signed written informed consent exclusion criteria: • patients suffering for any systemic disease or endocrine disorder will be excluded foe the study

Keywords: elisa saliva progesterone oestradiol early follicular phase mild follicular phase late follicular phase
strain for risk assessment and therapeutic strategies in patients with acute heart failure (strats-ahf) registry

Conditions: Heart Failure Acute; Heart Failure; Echocardiography

Summary: strats-ahf (strain for risk assessment and therapeutic strategies in patients with acute heart failure) registry enrolled 4,312 patients hospitalized for acute hf from 3 tertiary university hospitals (seoul national university bundang hospital, seoul national university hospital, and chungnam national university hospital) from january 2009 through december 2016.

patients with signs or symptoms of heart failure and either lung congestion, or objective findings of left ventricular (lv) systolic dysfunction or structural heart disease, were eligible for the study. echocardiography was performed and both lv ejection fraction (lvef) and lv global longitudinal strain (lv-gls), right ventricular gls (rv-gls) were measured.

Eligibility criteria:
inclusion criteria: * patients with signs or symptoms of hf and either lung congestion, or objective findings of lv systolic dysfunction or structural heart disease exclusion criteria: * patients who presented with acute coronary syndrome

Keywords: acute heart failure global longitudinal strain ejection fraction echocardiography mortality
medication-taking preferences & practices of patients with chronic conditions

Conditions: Any Condition in N73.0 Specified as Chronic; Adult Disease; Pharmacological Action

Summary: "patients can easily be overwhelmed, confused and many times don't fully understand their need for new medications, or when the dosages are to be administered" (patient research partner quote). the long-term goal of this study is to refine medication science by developing patient-centered assessment, monitoring and management guidelines for patients and health professionals. the objective is to advance knowledge about the medication-taking perspectives, experiences, and behaviors of older adults with multiple chronic medical conditions (mcmc) to inform future research related to patient-centered medication prescribing, monitoring and management. this pilot study addresses the following pcori interest area: "evaluating methods that can be used to assess the patient perspective when researching behaviors and choices within the patient's control that may influence outcomes." the rationale that underlies the proposed study is that medication-taking practices are wholly within patients' control, and are foundational to reducing complications and improving outcomes for those with mcmc. to meet the overall objective of this application, the following specific aims will be pursued: 1) identify perceptions and behaviors surrounding the medication-taking process of older adults with mcmc; and 2) generate an interpretation of the meaning of medication-taking among older adults with mcmc. to achieve these aims, data will be obtained in "real time" from patients (n=30) receiving a new prescription using smart phone technology. the smart phones will include prompts to help participants record thoughts about medication use throughout the day for 30 days. findings from electronic diaries will be logged, analyzed and qualitatively analyzed. some patients (n=15) will provide in-depth hermeneutic interviews to provide rich descriptions and interpretive commentary about the experience of receiving a new medication prescription. the objective is to uncover previously unidentified areas of common experience in older persons with multiple chronic conditions who have received a new prescription. common experiences and patterns of influences, that are often surprising or unexpected, will be categorized and assessed. the expected outcomes of this pilot study are improved knowledge of medication-taking perceptions, experiences, and practices of older adults with mcmc-knowledge that is critical to advance patient-centered medication science.


Eligibility criteria:
inclusion criteria: * 60 years of age or older * diagnosis of at least 3 chronic medical conditions * receiving 5 or more medications * receipt of a new prescription medication at enrollment * ability to speak english exclusion criteria: * any individual that does not meet the 5 inclusion criteria listed above

Keywords: multiple chronic conditions older adults new prescription
self- versus conventional-swabbing for covid-19 screening (coviswab)

Conditions: Covid19

Summary: self-swabbing requires less personal protective equipment and could allow to test more people and even to do quick self-diagnosis if antigenic tests are available. in a preliminary study on 190 medical students, the investigators have shown that self and conventional swabbing were identically well-accepted with equivalent level of pain and discomfort induced by swabbing. in a sub-group of this sample, the investigators have shown that the quality of the 2 sampling methods were equivalent. the goal of this large study in the general population is to confirm these findings in an adequately powered study. such results would allow to develop self-swabbing for large screening campaigns and eventually self-diagnosis using antigenic tests.

all consecutive subjects coming to the 2 dedicated centers for covid-19 screening in clermont-ferrand university hospital (one for medical students and one for the general population) will be asked to be included in the present study. they will be randomly assigned to either supervised self-swabbing followed by conventional swabbing led by a healthcare professional or the other way round. all the subjects will have to complete a brief questionnaire including demographical characteristics (age, sex, height, weight, eye color), potential symptoms (asthenia, fever, anosmia...) anticipated pain and discomfort and previous nasopharyngeal swabbing experience. pain, discomfort and overall acceptability of the procedure will be completed just after completion of the swabbing.

Eligibility criteria:
inclusion criteria: * any subject coming for nasopharyngeal swabbing for sars-cov-2 screening * fluent in french (both oral and written) * able to give an eclaired consent exclusion criteria: * contra-indication to nasopharyngeal swabbing * refusal to participate * pregnant women

Keywords: sars-cov-2 covid-19 nasopharyngeal swabbing self-swabbing pain sensitivity
combined diagnosis of ct and exosome in early lung cancer

Conditions: Early Lung Cancer

Summary: this experiment has now collected 50 cases, all through ct chest scans and blood exosome detection. twenty-two patients underwent surgical treatment and 14 tissue specimens were examined for cancer and paracancerous tissue exosomeswe found that exosomal micor-a was highly expressed in early stage lung cancer tissues and was significantly higher than paracancerous tissues. the micor-a in the adjacent tissues was significantly higher than that in peripheral blood exosomes


Eligibility criteria:
inclusion criteria:1. at least 18 years of age, male or female; 2. no patients with acute disease; 3. chest or ldct examination for the first time found 5-30mm pulmonary nodule patients, and ruled out disseminated tuberculosis; 4. past pulmonary nodes festival failed to diagnose. 5. have not received a history of surgical treatment of the lungs; 6. patients who have not received targeted drugs, biological treatments, immunosuppressive agents, and modulators; 7. no organ transplants; 8. signed informed consent before undergoing clinical studies consent and adherence to the research protocol. - exclusion criteria:1. pulmonary nodules have been treated surgically (considering that surgery has been performed to interfere with the study); 2. history of organ transplants such as lung transplantation (consider the use of allogeneic genes and immunosuppressive agents); 3. pregnancy or lactation (consider failure to perform regular ct follow-up and fetal component effects. 4. known hiv-positive or only aids-related diseases (taking into account interference with the use of immune drugs); 5. being targeted drugs, immunosuppressive agents, immunomodulators, biotherapies patients; 6. active pulmonary tuberculosis (consider infectious and referral missing factors); 7. rna-like viral infections: such as sars, hiv, hepatitis virus (except for hepatitis b, the other four are all rna viruses), influenza virus, bird flu virus, h5n1, ebola, measles, etc. 8. various blood system diseases such as leukemia, lymphoma, aplastic anemia, myelodysplastic syndrome, anemia, hemolysis, hemophilia, dic, etc. 9. recent history of blood transfusion (within 3\~6 years) and potential for blood transfusion; 10. patients with neurological disorders and mental disorders unable to cooperate; 11. emergency treatment for acute and severe diseases; 12. no willing to sign a written informed consent and follow the study protocol before they are willing to conduct clinical research; 13. the presence of the patient may interfere with any psychological, family, social or geography conditions that obey the requirements of the research protocol or the follow-up procedure. discuss these conditions with the patient before entering the study. -

Keywords: early lung cancer,ground-glass nodule,ct,exosome
evaluation of rare and complex tumours of the thoraco-abdominal and soft tissue district

Conditions: Rare Malignant Neoplasm

Summary: the goal of this observational study is to collect structured data about diagnosis, treatment and follow-up of rare and highly complex neoplasms. the study has a rerospective part that will consist in gathering data on patients accessing irccs azienda ospedaliero-universitaria di bologna policlinico di s. orsola from 01/01/2000 to 28/09/2017 and a prospective one ranging from 29/09/2017 to 31/12/2025.


Eligibility criteria:
inclusion criteria: * patients with histologic diagnosis of rare or highly complex malignant neoplasm * informed consent exclusion criteria: * none
a prospective observational study of lymphedema in breast cancer with axillary lymph node dissection

Conditions: Breast Cancer

Summary: over the past few years, several studies have been made on various outcomes about the incidence of lymphedema. because the outcomes can be came out differently each study by measurement, criteria, treatment period, treatment method and morbid extremities of lymphedema. therefore it is required for understanding about the incidence, risk factor and physical progress for to be treated and prevented of lymphedema. also it is necessary that to understand characteristics of lymphedema measurements and to establish diagnostic criteria of lymphedema through comparative study. the aim of this study was to analyze the incidence and risk factor of lymphedema through prospectively observation, and to determine effects on the quality of life of lymphedema after breast cancer surgery with alnd.

primary objectives: - to analyze incidence rate of lymphedema using tape measurements, perometre, bioimpedance, spectroscopy. secondary objectives: * to determine the risk factor of lymphedema in postoperative breast cancer. * to understand that lymphedema has an effect on quality of life and physical function in postoperative breast cancer. * to complete uestionnaire about physical and quality of life in postoperative breast cancer with alnd patients.

Eligibility criteria:
inclusion criteria: * older than 20 years old * patient who underwent unilateral breast cancer surgery with alnd * informed consent must to be signed exclusion criteria: * previous history of breast cancer * history of abnormality or vascular disease in upper extremity * patients with other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate. * history of infection on upper extremity * history of corticosteroid use on whole body for any reason * inability to provide informed consent (e.g. dementia or severe cognitive impairment)

Keywords: breast cancer, axillary lymph node dissection, lymphedema
study of tumor samples from patients with ewing sarcoma

Conditions: Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Summary: this laboratory study is looking at tumor samples from patients with ewing sarcoma. studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer

study subtype: ancillary/correlative observational study model: cohort time perspective: prospective biospecimen retention: samples with dna biospecimen description: tissue study population description: samples collected from aews0031 and patients registered on aews08b1 sampling method: non-probability sample primary objectives: i. determine if mutation of p53, and/or deletion of the p16 locus, have prognostic value in patients with ewing sarcoma. secondary objectives: i. estimate the incidence of p53 mutation in ewing sarcoma samples collected from cog studies. ii. estimate the incidence of p16 deletions in ewing sarcoma samples collected from cog studies. iii. prepare and archive amplified genomic dna from ewing sarcoma samples collected from cog studies for future biologic analysis. outline: this is a multicenter study. previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, fish, pcr, and dna sequencing.

Eligibility criteria:
inclusion criteria: * diagnosis of ewing sarcoma * banked specimens from patients enrolled on aews0031
the use of natural latex biomembrane in ocular surface reconstruction

Conditions: Conjunctival Diseases; Pterygium

Summary: the main problem of ocular surface reconstruction is the lack of viable conjunctival tissue. the use of a biocompatible latex biomembrane in ocular surface healing, like post pterygium surgery, could be an alternative therapeutic resource to this process.

the latex biomembrane is considered biocompatible and believed to promote neoformation of biological tissues. it also induces vascular neoformation and promotes extra cellular provisional matrix formation, fundamental steps for any kind of wound healing. in humans, it was successfully used in chronic cutaneous ulcer and otologic surgeries. in rabbits' eyes, the latex biomembrane was efficient in ocular surface reconstruction with adequate conjunctiva functional recovery, compared to bare sclera. to study the latex biomembrane action in human ocular surface, it was compared to conjunctival autograft in humans eyes. considering the deficiency of adequate sized groups and the pterygium recurrences criteria differences, this study proposes the fibrovascular tissue growing measure like an auxiliary method of pos-operative evaluation. the biomembrane of natural latex seems to be efficient in ocular surface reconstruction and must be employed in future studies of other ocular pathologies. this material revealed to be a new source of therapeutic resort to external eye diseases and conjunctival replace in surgeries living bare sclera.

Eligibility criteria:
inclusion criteria: * symptomatic pterygium exclusion criteria: * any other ocular surface pathology, glaucoma, retinal disease, pregnancy, auto immune disease, severe systemic disease

Keywords: ocular surface reconstruction conjunctival healing pterygium latex biomembrane pterygium surgery
acute cardioversion versus wait and see-approach for symptomatic atrial fibrillation in the emergency department

Conditions: Atrial Fibrillation

Summary: a symptomatic episode of the heart rhythm disorder 'atrial fibrillation' (af) is a frequent reason for visits to the emergency department. currently, in the majority of cases, immediate (electrical or pharmacological) cardioversion is chosen, while atrial fibrillation terminates spontaneously in 70% of the cases within 24 hours. a wait-and-see approach with rate-control medication only, and when needed cardioversion within 48 hours of onset of symptoms, could be effective, safe and more cost-effective than current standard of care and could lead to a higher quality of life.


Eligibility criteria:
inclusion criteria: * ecg with atrial fibrillation at the emergency department * heart rate \> 70bpm * symptoms most probable due to atrial fibrillation * duration of symptoms \< 36 hours * \> 18 years of age * able and willing to sign informed consent * able and willing to use mydiagnostick exclusion criteria: * signs of myocardial infarction on ecg * hemodynamic instability (systolic blood pressure \ 170 bpm) * presence of pre-excitation syndrome * history of sick sinus syndrome * history of unexplained syncope * history of persistent af (episode of af lasting more than 48 hours) * acute heart failure * currently enrolled in another clinical trial * deemed unsuitable for participation by attending physician

Keywords: atrial fibrillation electrical cardioversion pharmacological cardioversion rhythm control rate control
early detection of pancreatic cancer in patients with papillary and mucinous intracanal tumours of the pancreas papillary and mucinous tumours of the pancreas

Conditions: PAPILLARY AND MUCINOUS INTRACANAL TUMORS OF THE PANCREAS

Summary: this trial is a prospective, exploratory and descriptive study. the primary objective is to identify early diagnostic biomarkers in patients with tipmp based on the analysis of treg lymphocyte subpopulations and epigenetic signatures, and the secondary objective is to characterize the biological processes underlying the transformation of a pre-neoplastic lesion into established adpc.

to meet the objectives of the study, patients will have blood samples taken at the time of their tipmp monitoring, i.e. at inclusion, 6 months, 1 year and 2 years. if echo-endoscopy is performed during mri monitoring of their disease, and a sample is taken as part of the treatment, a tumor sample and an intra-cystic fluid sample will be collected as part of the protocol.

Eligibility criteria:
inclusion criteria: 1. age over 18 2. patient with intermediate-risk or high-risk tipmp according to the european study group on cystic tumours of the pancreas (3) 3. signed consent to participate 4. affiliation with a social security scheme, or beneficiary of such a scheme. exclusion criteria: 1. pregnant or breast-feeding woman 2. person in an emergency situation or unable to give consent. 3. adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice), 4. unable to undergo medical follow-up for geographical, social or psychological reasons. 5. contraindication to mri.